VNDA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VNDA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Vanda Pharmaceuticals's enterprise value is $-85.5 Mil. Vanda Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-10.9 Mil. Therefore, Vanda Pharmaceuticals's EV-to-EBITDA for today is 7.82.
The historical rank and industry rank for Vanda Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
During the past 13 years, the highest EV-to-EBITDA of Vanda Pharmaceuticals was 441.02. The lowest was -188.10. And the median was -6.20.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-13), Vanda Pharmaceuticals's stock price is $5.04. Vanda Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.052. Therefore, Vanda Pharmaceuticals's PE Ratio for today is 96.92.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
The historical data trend for Vanda Pharmaceuticals's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vanda Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
EV-to-EBITDA | Get a 7-Day Free Trial | 22.61 | 12.18 | 10.15 | -3.98 | 12.44 |
Vanda Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
EV-to-EBITDA | Get a 7-Day Free Trial | -3.98 | -5.39 | -8.15 | -101.26 | 12.44 |
For the Biotechnology subindustry, Vanda Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Vanda Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Vanda Pharmaceuticals's EV-to-EBITDA falls into.
Vanda Pharmaceuticals's EV-to-EBITDA for today is calculated as:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
= | -85.543 | / | -10.942 | |
= | 7.82 |
Vanda Pharmaceuticals's current Enterprise Value is $-85.5 Mil.
Vanda Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vanda Pharmaceuticals (NAS:VNDA) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Vanda Pharmaceuticals's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 5.04 | / | 0.052 | |
= | 96.92 |
Vanda Pharmaceuticals's share price for today is $5.04.
Vanda Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.052.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Please read Which price ratio outperforms the enterprise multiple?
Thank you for viewing the detailed overview of Vanda Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Joakim Wijkstrom | officer: SVP, Chief Marketing Officer | 2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON, DC DC 20037 |
Stephen Ray Mitchell | director | C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVE., SUITE 300E, WASHINGTON DC 20037 |
Kevin Patrick Moran | officer: VP, Acting CFO & Treasurer | C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037 |
Timothy Williams | officer: SVP & General Counsel | C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE NW, SUITE 300E, WASHINGTON DC 20037 |
Tage Honore | director | C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037 |
Mihael Hristos Polymeropoulos | director, officer: Chief Executive Officer | 9605 MEDICAL CENTER DRIVE SUITE 300, ROCKVILLE MD 20850 |
Gunther Birznieks | officer: SVP, Business Development | 2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON DC 20037 |
Thomas Watkins | director | 1221 GULF SHORE BLVD N #303, NAPLES FL 34102 |
Aranthan Ii Jones | officer: Chief Corp. Affairs Officer | 2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON DC DC 20037 |
Phaedra Chrousos | director | 2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON DC 20037 |
Richard W Dugan | director | 20425 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876 |
James Patrick Kelly | officer: SVP, CFO, Treasurer & Secretar | C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850 |
Gian Piero Reverberi | officer: SVP, General Manager Europe | 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037 |
Anne Sempowski Ward | director | C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037 |
Vincent Milano | director | C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341 |
From GuruFocus
By PRNewswire PRNewswire • 06-02-2023
By PRNewswire PRNewswire • 03-28-2023
By PRNewswire PRNewswire • 05-25-2023
By PRNewswire PRNewswire • 06-05-2023
By PRNewswire • 01-04-2024
By PRNewswire • 07-27-2023
By PRNewswire • 01-17-2024
By PRNewswire • 11-14-2023
By GuruFocus Research • 11-08-2023
By PRNewswire • 01-19-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.